Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Gets Additional $8.4M in NIEHS Funding for Toxicogenomics

NEW YORK, April 24 - Paradigm Genetics will receive an additional $8.4 million from the National Institute of Environmental Health Sciences for toxicogenomics studies, in addition to $23.8 million already funded under a five-year contract, the company said today.


The original contract calls for Paradigm researchers to use a gene-expression platform based on technology developed at Agilent Technologies to discern what happens to an organism when an undisclosed variety of toxicants, drugs, and pesticides have been introduced.


Of this additional funding, $2 million will go toward research for the National Toxicology Program, an interagency program that involves the NIEHS, the US Centers for Disease control's National Institute for Occupational Safety and Health, and the FDA's NationalCenterfor Toxicological Research. The research will involve NTP's efforts to understand the effects of chemical exposure, using DNA microarray analysis, the company said.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.